[Development of resistance to nalidixic acid in experiments in vitro and cross resistance with other preparation in pathogenic and nonpathogenic strains of E. coli].
D000328:Adult; D000667:Ampicillin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002509:Cephaloridine / Q000494:pharmacology; D002648:Child; D002701:Chloramphenicol / Q000494:pharmacology; D002751:Chlortetracycline / Q000494:pharmacology; D003091:Colistin / Q000494:pharmacology; D004751:Enteritis / Q000382:microbiology; D015643:Erythromycin Ethylsuccinate / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects* / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000382:microbiology; D006801:Humans; D007612:Kanamycin / Q000494:pharmacology; D009268:Nalidixic Acid / Q000494:pharmacology*; D009355:Neomycin / Q000494:pharmacology; D009827:Oleandomycin / Q000494:pharmacology; D010118:Oxytetracycline / Q000494:pharmacology; D010403:Penicillin Resistance; D011113:Polymyxins / Q000494:pharmacology; D013307:Streptomycin / Q000494:pharmacology; D013752:Tetracycline / Q000494:pharmacology; D014756:Viomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D011113:Polymyxins; D015643:Erythromycin Ethylsuccinate; D009268:Nalidixic Acid; D007612:Kanamycin; D002701:Chloramphenicol; D000667:Ampicillin; D013752:Tetracycline; D009355:Neomycin; D002509:Cephaloridine; D009827:Oleandomycin; D002751:Chlortetracycline; D010118:Oxytetracycline; D013307:Streptomycin; D014756:Viomycin; D003091:Colistin
Razvitie ustoĭchivosti k nalidiksovoĭ kilote v opytakh in vitro perekrestnoĭ ustoĭchivosti s drugimi preparatami u patogennykh i nepatogennykh shtammov E. coli.